Matinas Biopharma Holdings Inc (MTNB) - News Archive

Matinas BioPharma s Strategic Moves: Acquisition of Preferred Stock and Board Expansion Amidst Market ChallengesIn a transformative move designed to bolster its financial standing and strategic growth, Matinas BioPharma...

Matinas BioPharma Holdings, Inc. has recently reported a remarkable success in treating a 22-year-old male patient with polymicrobial necrotizing fasciitis caused by the drug-resistant fungus, Mucorales. This breakthrou...

In an exciting development, the renowned CSIMarket.com is proud to present an exclusive fireside chat hosted by A.G.P., featuring esteemed antifungal expert, Dr. David S. Perlin, and pharmaceutical company Matinas BioPh...

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) has recently presented new in vitro data highlighting the potential of its lipid nanocrystal (LNC) platform technology for delivering small oligonucleotides. This b...

Combining Science and Innovation: Matinas BioPharma s MAT2203 Shows Promise in Fighting Pulmonary MucormycosisStudies conducted on a neutropenic mouse model have revealed groundbreaking results in the battle against pul...

Matinas BioPharma Raises $10 Million in Direct Offering to Address Continued Listing DeficiencyMatinas BioPharma Holdings, Inc. recently announced a successful $10 million registered direct offering, issuing 33,333,334...

Matinas BioPharma, a clinical-stage biopharmaceutical company focused on developing innovative therapies for serious and life-threatening diseases, has delivered positive updates on the safety and efficacy of its oral L...

Matinas BioPharma s MAT2203 shows promising results in invasive fusarium infection treatmentIn a major breakthrough, Matinas BioPharma Holdings, Inc. has announced complete clinical response in three patients suffering...

This article aims to provide an overview of the positive outcomes reported by Matinas BioPharma on their MAT2203 Compassionate/Expanded Use Access Program. The program enrolled 19 patients with serious and life-threaten...

Matinas BioPharma, a clinical-stage biopharmaceutical company, has recently announced that it has successfully reached an agreement with the U.S. Food and Drug Administration (FDA) for a single Phase 3 registration tria...

Matinas BioPharma Advances Inflammatory Disease Treatment with Oral LNC-Delivered Small OligonucleotidesIn a groundbreaking study, Matinas BioPharma has demonstrated impressive in vivo biological activity and disease im...

In an exciting development for Matinas BioPharma, the company recently received written preliminary comments from the Food and Drug Administration (FDA) on the Phase 3 registration trial for its leading drug candidate,...

Matinas BioPharma, a clinical-stage biopharmaceutical company known for its groundbreaking lipid nanocrystal (LNC) platform technology, recently announced that it has received a deficiency letter from NYSE American LLC...